MTAP and renal cell carcinoma: Significantly, the genomic alteration of MTAP prominently predicted shorter DSS (P < 0.0001, HR=5.675), PFS (P < 0.0001, HR = 6.000), DFS (P < 0.0001, HR = 6.008), and OS (P < 0.0001, HR = 3.669) in patients with RCC from the Western testing cohort (Figure 3A).